This is a working overview of Research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | LC-MS and HPLC | Used for identity and purity assessment. |
| Purity specification | ≥95% or ≥98% in research grades | Actual purity depends on supplier and batch. |
| Stability in solution | Limited; prepare fresh | Aqueous and organic stocks may degrade over time. |
| Recommended storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles. |
| Regulatory status | Not approved for human use | Sold as a research chemical in some regions. |
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
=== Middle Eastern countries === As of March 2026, Nando's has five restaurants in Bahrain; two in Manama and one each in Amwaj Islands, Isa Town and Saar. In Qatar, Nando's has been established since 2001, with the first restaurant located on Salwa Road. As of October 2022, Nando's has eight branches in Qatar, seven of which are located in Doha while one is in Al Wakrah. In Saudi Arabia, Nando's opened its first restaurant within the country on 12 December 2016 in Riyadh, and opened its first branch in Jeddah on 8 December 2018 As of March 2026, Nando's has nine branches in Saudi Arabia; three in Riyadh, three in Jeddah; and one each in Dhahran, Dammam and Khobar. Nando's opened its first restaurant within the United Arab Emirates in Dubai (along Sheikh Zayed Road) in 2002 and opened its first branch in Abu Dhabi in 2014. As of August 2021, Nando's has 19 branches in the UAE; 13 in Dubai, three in Abu Dhabi and one each in Sharjah, Al Ain and Ras Al Khaimah. As a former market, Israel was home to a successful Nando's franchise network throughout the 1990s and 2000s, with the Israeli operation involving the Brozin brothers alongside the international Nando's business. The first Israeli branch opened in Herzliya in 1993, and by 1996 there were branches in Tel Aviv, Herzliya and Haifa, with plans for further expansion. By March 2004, the network had grown to 15 restaurants. In December 2005, Nando's Israel was acquired by Israeli businessman Yuval Doron's Eddy Global Holdings. Kenny Brozin remained chief executive of the Israeli operation until June 2006.
== Participation in the creation-evolution debate == Wickramasinghe and his mentor Fred Hoyle have also used their data to argue in favor of cosmic ancestry, and against the idea of life emerging from inanimate objects by abiogenesis.
== Legal status == Valerylfentanyl is a Schedule I controlled drug in the USA since 1 February 2018. In December of 2019, the UNODC announced scheduling recommendations placing valerylfentanyl into Schedule I.
=== Justin Klineman === Justin Klineman (Joshua James) is Pierpoint's head of HR. He is first seen pressing Harper to send over her college transcripts, unaware she never graduated; Harper sends forged documents. Eric, aware of Harper's past, reports her deceit to HR at the end of series 2, and Justin fires her. In series 3, Justin and another HR rep confront Rishi over his lewd and inappropriate comments on the trading floor, which he angrily dismisses. After Pierpoint is acquired by Al-Mi'raj, a holding company for the Egyptian sovereign wealth, the London trading firm is shut down, and Justin presides over a slew of employee terminations including Eric's.
==== Voice acting ==== Shawn is a voice actor for animated films and television series, including the Toy Story franchise, Monsters, Inc. (during the outtakes in the closing credits), Kingdom Hearts III, The Incredibles, A Goofy Movie, Family Guy, Happily N'Ever After, Tom and Jerry: Shiver Me Whiskers, Regular Show, BoJack Horseman and Animal Crackers. Shawn said that Toy Story director John Lasseter might have seen both My Dinner with Andre and The Princess Bride and seen him as "excitable" like Shawn's character, Rex. During production of The Fox and the Hound, Shawn was originally cast as Boomer, but dropped out and was replaced by Paul Winchell. In Cats & Dogs: The Revenge of Kitty Galore, he replaced Jon Lovitz as the voice of Calico. He also voiced Mr. Mustela in The Addams Family 2.
Sources: en.wikipedia.org
=== May === May 1 Iran war: President Donald Trump notifies lawmakers in Congress that the Iran war has been "terminated" ahead of a 60-day deadline under the War Powers Resolution which military operations must halt unless lawmakers authorize military force. 2026 May Day protests: May Day protests are held across the U.S., including an economic blackout as part of 3,500 "May Day Strong" events across the country. Additionally, demonstrations are held outside institutions such as the New York Stock Exchange. British singer Zayn Malik cancels all U.S. concert events for his upcoming Konnakol tour after being hospitalized for an unknown illness. May 2 2026 Kentucky Derby: In horse racing, American racehorse Golden Tempo wins the 152nd Kentucky Derby after entering the race with a 24–1 odds, making Cherie DeVaux the first female trainer to win the derby. Spirit Airlines announces it has gone out of business after 34 years. May 3 – Iran war: President Trump announces Operation Project Freedom in an effort to secure commercial traffic across the Strait of Hormuz. May 4 Iran war: The U.S. Central Command confirms the launch of Operation Project Freedom in an effort to secure commercial traffic across the Strait of Hormuz. Danish shipping company Maersk reports that the Alliance Fairfax, a US-flagged vehicle carrier operated by subsidiary Farrell Lines, has successfully crossed the Strait of Hormuz accompanied by U.S. military assets as part of Project Freedom. Iran is reported to have fired missiles and drones at military and commercial ships.
The francium atoms leave the gold target as ions, which are neutralized by collision with yttrium and then isolated in a magneto-optical trap (MOT) in a gaseous unconsolidated state. Although the atoms only remain in the trap for about 30 seconds before escaping or undergoing nuclear decay, the process supplies a continual stream of fresh atoms. The result is a steady state containing a fairly constant number of atoms for a much longer time. The original apparatus could trap up to a few thousand atoms, while a later improved design could trap over 300,000 at a time. Sensitive measurements of the light emitted and absorbed by the trapped atoms provided the first experimental results on various transitions between atomic energy levels in francium. Initial measurements show very good agreement between experimental values and calculations based on quantum theory. The research project using this production method relocated to TRIUMF in 2012, where over 106 francium atoms have been held at a time, including large amounts of 209Fr in addition to 207Fr and 221Fr. Other synthesis methods include bombarding radium with neutrons, and bombarding thorium with protons, deuterons, or helium ions. 223Fr can also be isolated from samples of its parent 227Ac, the francium being milked via elution with NH4Cl–CrO3 from an actinium-containing cation exchanger and purified by passing the solution through a silicon dioxide compound loaded with barium sulfate.
=== Effects in nondiabetic chronic kidney disease === In 2021, the US Food and Drug Administration (FDA) and the EMA expanded the indications for dapagliflozin to include the treatment of people who have chronic kidney disease, but do not have diabetes. Clinical trials have shown these effects of such a treatment: The DIAMOND trial (2017–2019) in treatment periods of six weeks showed no improvement of excess proteins in the urine (proteinuria), a significant deterioration of the kidney's filtration rate (reversible within 6 weeks after dapagliflozin discontinuation), and a significant mean loss of body weight of 1.5 kg. The DAPA-CKD trial (2017–2020) showed in a median treatment period of 2.4 years of participants who had already been under ACE inhibitor or angiotensin II receptor blocker therapy that the events of a sustained decline of 50% in the kidney's filtration rate, kidney failure, or death occurred statistically around eight months later in the treatment group than in the placebo group. In the first 12–16 months of treatment, but the kidney filtration rate was worse in the treatment group than in the placebo group, being slightly less negative in the treatment group than in the placebo group only thereafter.
Nicotine dependence pathophysiology in heavy smokers suggests less efficient network architecture in the brain and disruptions in the topological organization of brain networks, with the altered brain network metrics correlated with the duration of cigarette use and the severity of nicotine dependence. Some long-term effects of nicotine may be irreversible because "it is entirely possible that doses of nicotine achieved in the brains of human smokers can damage or kill mHb [medial habenula] neurons that regulate nicotine avoidance behaviors", but more studies are needed to elucidate this underlying mechanism of nicotine-induced degeneration of the mHb-IPn circuit . A 2026 Nature study revealed that nicotine mimics endogenous acetylcholine in the nucleus accumbens, artificially triggering dopamine release to biologically "tag" behaviors as valuable, high-effort achievements regardless of actual difficulty. During active use, this chemical shortcut causes salience dysregulation and "false productivity," as the brain assigns intense reward signals to trivial tasks independent of outcome quality while displacing ambition for a meaningful achievement.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.
Dihexa is often described as an HGF mimetic that activates c-Met signaling. Some research also links it to angiotensin IV pathways. The precise targets and human relevance remain uncertain.
The powder is typically stored at -20 °C, desiccated and protected from light. Avoid repeated freeze-thaw cycles. Follow supplier instructions and institutional guidelines.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.